Dr. Bruce N. Ames, Ph.D.
(Founder, Director, and Chairman of the Scientific Advisory Board) is a Professor of Biochemistry and Molecular Biology at the University of California, Berkeley. Dr. Ames is also Senior Scientist, Children’s Hospital of Oakland Research Institute. He is a member of the National Academy of Sciences and he was on their Commission on Life Sciences. He was a member of the board of directors of the National Cancer Institute, the National Cancer Advisory Board, from 1976 to 1982.

He was the recipient of a leading award for cancer research, the General Motors Cancer Research Foundation Prize (1983), a leading award in environmental achievement, the Tyler Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), and the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Achievement in Excellence Award of the Center for Excellence in Education (1996), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize, (1997), and the Kehoe Award, American College of Occupational and Environmental Med. (1997), the Medal of the City of Paris (1998), the Joseph Priestley Award (1998), and the U.S. National Medal of Science (1998). His over 400+ publications have resulted in his being among the few hundred most-cited scientists in all fields: 23rd most cited (1973-1984).

Professor Ames has been the international leader in the field of mutagenesis and genetic toxicology for over 20 years. His work has had a major impact on, and changed the direction of, basic and applied research on mutation, cancer, and aging. The development of the Ames mutagenicity test as a practical tool for the detection of potential carcinogens has led to its use in over 3000 laboratories and in all of the major drug and chemical companies, where it has had a major influence in weeding out mutagenic chemicals while it is cheap to do so and before they are introduced into commerce. Dr. Ames' current research focuses on the oxidative damage to DNA and its relationship to mutagenesis, carcinogenesis and the degenerative diseases of aging. His main interest is in the prevention of cancer and other degenerative diseases of aging.

Dr. M. Flint Beal, M.D.
is professor and chairman of the department of neurology and neuroscience at the Weill Medical College of Cornell University and Neurologist-in- Chief at the New York-Cornell campus of New York Presbyterian Hospital.

Previously, Dr. Beal was professor of neurology at Harvard Medical School was chief of the neurochemistry laboratory and director of the clinical trials unit in the department of neurology at Massachusetts General Hospital (MGH). He received his medical degree from the University of Virginia in 1976 and did his internship and first-year residency in medicine at New York-Cornell before beginning his residency in neurology at MGH. He joined the neurology faculty at Harvard in 1983.

Dr. Beal has authored some 350 articles, book chapters and peer reviews on topics such as oxidative damage in Alzheimer's and mitochondria research in Parkinsonian patients. He serves on the editorial boards of the Journal of Neurochemistry, the Annals of Neurology, Molecular and Chemical Neuropathology, the Alzheimer's Disease Review and the Journal of Contemporary Neurology.

His research has focused on the mechanisms of neuronal degeneration in Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). He has also been working on the development of novel neurochemical assays for assessing oxidative damage for use in clinical trials of new therapies for these disorders.

Dr. Ervin Epstein, Jr., M.D.
is a leading Dermatologist whose research interests have focused on the molecular biology of inherited and neoplastic skin diseases. Dr. Epstein is also a frequent speaker and leading writer with papers that have appeared in New England Journal of Medicine and Science. He has also served on the boards of numerous dermatological organizations as well as journals, including American Academy of Dermatology and Journal of Investigative Dermatology and has served as President of the Society for Investigative Dermatology, the world's foremost organization devoted to research into the biology of the skin. Currently, Dr. Epstein serves as the Research Dermatologist and Clinical Professor of Dermatology at the University of California, San Francisco and has an active private practice in the San Francisco Bay Area.

Dr. Tory Hagen, Ph.D.
is co-inventor with Dr. Ames on the patent that Juvenon has licensed from the University of California, Berkeley, and co-author with Dr. Ames of Mitochondrial Decay in Aging and its Consequences to the Cell. Dr. Hagen is Associate Professor, Department of Biochemistry and Biophysics and Principal Investigator at the Linus Pauling Institute at Oregon State University, Corvallis, OR. Previously Dr. Hagen was a Post-doctoral Fellow and Assistant Specialist Research Scientist in the Department of Molecular and Cell Biology at the University of California, Berkeley. He earned his Ph.D. in biochemistry at Emory University.

Dr. Hagen's current research is focused on the degenerative diseases of aging, mitochondrial decay in aging, and the impact of alpha-lipoic acid on mitochondrial function.

Dr. Benjamin Treadwell, Ph.D.
is an independent researcher in biochemistry with a life-long interest in metabolism and aging. He previously served as an Associate Professor of Biochemistry at Harvard Medical School and as Director of the Orthopedic Research Laboratory at Massachusetts General Hospital. He earned his Ph.D. in biochemistry at New York University and served as a Research Fellow at the Roche Institute of Molecular Biology in New Jersey.

Dr. Treadwell's current interest is with designing studies to help understand the biochemical basis of aging in humans. The focus of these studies will be to convert the inefficient energy-producing machinery of the cells in aged humans to those resembling the more efficient youthful cell. The studies will involve clinical trials to test the effectiveness of specific natural compounds that are demonstrated to be deficient in aged tissues, and believed to be at least partially responsible for the energy deficit characteristic of the aged cell. These studies will be closely linked to the Ames and Hagan laboratories where pioneering work with animal and cell studies has demonstrated various age-related changes in cellular and organelle structure.

Dr. Treadwell's mission is to further characterize, and analyze the results obtained from animal and cell studies, with the purpose of translating those results into a rational design (regimen of compounds) appropriate for human studies. His goal is to develop a combination of compounds, or compound cocktail, packaged in a tablet form that when taken on a regular basis by humans will result in significant improvement in overall health and quality of life.